Sangamo BioSciences (SGMO) Stock Soars on First-In-Man Study of Genome Editing Tech

Shares of Sangamo Biosciences Inc. (SGMO) were trading at $23.50, up +3.89 or +19.84 percent in pre-market trading Thursday morning, after news late yesterday that the New England Journal of Medicine was publishing results of the first study of the companyâ s proprietary zinc finger nuclease (ZFN) genome editing technology in human beings.

Sangamo Bio stock closed at $19.61, up +0.69 or +3.65 percent in Wednesdayâ s regular trading session.
Richmond, California based Sangamo Biosciences Inc. is a clinical stage biopharmaceutical firm specializing in the research, development and commercialization of technology using engineered DNA binding proteins to develop new therapies for treating disease. The companyâ s zinc finger nucleases (ZFN) technology modifies the DNA of a cell at its location, thereby affecting a specific gene. The study published in the New England Journal of Medicine, covers the first clinical trial of the companyâ s ZFN based genome editing technology in humans. Data from the report, demonstrated in subjects who were HIV-positive, that the T-cell genome could be safely engineered to mimic a natural mutation resistant to HIV infection. Sangamo Bioâ s therapy, known as SB-728, could potentially be a cure for HIV/AIDS. The therapy basically removes some of the immune cells in the patientâ s blood attacked by the HIV. The blood is then treated in a lab where the SB-728 treatment is applied to the immune cells. The treatment removes the protein gateway on the immune cells which the HIV infects. The cells which have been treated are then re-introduced into the patient where they reproduce and overcome the HIV, which attacks and kills the non-treated cells. The treated cells then control the HIV infection, thus curing the patient of any other infections that would have resulted from the HIV. Richard W. Vague Professor in Immunotherapy at the department of Pathology and Laboratory Medicine at the University of Pennsylvania and co-author of the paper stated that, â

Published on Mar 6, 2014
By Jay Hawk
Jay Hawk
Jay Hawk enjoyed a 12-year professional financial markets career incorporating extensive first hand futures and options experience obtained by trading in the stock, commodity and forex markets on U.S. exchanges. Since retiring as a full-time financial market professional, he has been actively trading stock, commodities, forex and options for his own account and managing funds for others, as well as writing financial market commentary and educational articles.

Copyrighted 2016. Content published with author's permission.

Posted in ...